Effects of Interferons and Tumour Necrosis Factor-α on Human Lung Cancer Cell Lines and the Development of an Interferon-Resistant Lung Cancer Cell Line

References

• Ginsberg R. T., Kris M. G., Armstrong J. G., Idhe D. C., Pass H., Glatstein E. J. Cancer of the lung, VT de Vita, Jr, S. Hellam, S. Rosenberg. J. B. Lippencott Company. 1993; 673–758
   Google Scholar
• Linnoila R. I., Mulshine J., Steinberg S., Funa K., Matthews M. J., Cotelingam J., Gazdar A. F. Neuroendocrine differentiation in endocrine and nonendocrine lung carcinomas. Am J Clin Path 1988; 90: 1–12
   PubMedGoogle Scholar
• Asher A., Mule J. J., Reichert C. M., Shiloni E., Rosenberg S. A. Studies on the antitumor efficacy of systemically administered recombinant human tumor necrosis factor against several murine tumors in vivo. J Immunol 1987; 138: 963–74
   PubMed Web of Science ®Google Scholar
• Wadler S., Schwartz E. L. Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: A review. Cancer Res 1990; 50: 3473–86
   PubMed Web of Science ®Google Scholar
• Frei E, III, Spriggs D. Tumor necrosis factor: still a promising agent. J Clin Oncol 1989; 7: 291–4
   PubMed Web of Science ®Google Scholar
• Twentyman P. R., Workman P., Wright K. A., Bleehen N. M. The effects of α and γ interferons on human lung cancer cells grown in vitro or as xenografts in nude mice. Br J Cancer 1985; 52: 21–9
   PubMedGoogle Scholar
• Giaccone G., Kadoyama C., Maneckjee R., Venzon D., Alexander R. B., Gazdar A. F. Effects of tumor necrosis factor, alone or in combination with topoisomerase-II-targeted drugs, on human lung cancer cell lines. Int J Cancer 1990; 46: 326–9
   PubMed Web of Science ®Google Scholar
• Camey D. N., Gazdar A. F., Bepler G., et al. Establishment and identification of small cell cancer cell lines having classic and variant features. Cancer Res 1985; 45: 2913–23
   PubMedGoogle Scholar
• Bergh J., Larsson E., Zech L., Nilsson K. Establishment and characterization of two neoplastic cell lines (U-1285 and U-1568) derived from small cell carcinoma of the lung. Acta Pathol Microbiol Immun Scand Sect A 1982; 90: 149–58
   PubMedGoogle Scholar
• Bergh J., Nilsson K., Ekman R., Giovanella B. Establishment and characterization of cell lines from human small cell and large cell carcinomas of the lung. Acta Pathol Microbiol Immun Scand Sect A 1985; 93: 133–47
   PubMedGoogle Scholar
• Bergh J., Nilsson K., Zech L., Giovanella B. Establishment and characterization of a continuous lung squamous cell carcinoma cell line. Anticancer Res 1981; 1: 317–22
   PubMedGoogle Scholar
• de Leij L., Poppema S., Nulend J. K., et al. Neuroendocrine differentiation antigen on human lung carcinoma and Kulchitski cells. Cancer Res 1985; 45: 2192–200
   PubMedGoogle Scholar
• Okabe T., Kaizu T., Ozawa K., Urabe A., Takaku F. Elimination of small cell lung cancer cells in vitro from human bone marrow by a monoclonal antibody. Cancer Res 1985; 45: 1930–3
   PubMedGoogle Scholar
• Nilsson O., Brezicka F. T., Holmgren J., et al. Detection of a ganglioside antigen associated with small cell lung carcinomas using monoclonal antibodies directed against fucosyl-GMI. Cancer Res 1986; 46: 1403–7
   PubMed Web of Science ®Google Scholar
• Sundström C., Nilsson K. Establishment and characterization of a human histiocytic lymphoma cell line (U-937). Int J Cancer 1976; 17: 565–77
   PubMed Web of Science ®Google Scholar
• Larsson R., Nygren P. Pharmacological modification of multidrug resistance in vitro detected by a novel fluorometric microculture cytotoxicity assay. Resistance reversal and selective cytotoxic actions of cyclosporin A and verapamil on MDR leukemia T-cells. Int J Cancer 1990; 46: 67–73
   PubMedGoogle Scholar
• Larsson R., Nygren P., Ekberg M., Slater L. Chemotherapeutic drug sensitivity testing of human leukemia cells using a semiautomated fluorometric assay. Leukemia 1990; 4: 567–71
   PubMed Web of Science ®Google Scholar
• Larsson R., Kristenssen J., Sandberg C., Nygren P. Laboratory determination of chemotherapeutic drug resistance in tumor cells from patients with leukemia using a fluorometric microculture cytotoxicity assay. Int J Cancer 1992; 50: 177–85
   PubMed Web of Science ®Google Scholar
• Mogensen K. E., Bandu M-T, Vignaux F., Aguet M., Gresser I. Binding of [125I]-labeled human alpha interferon to human lymphoid cells. Int J Cancer 1981; 28: 575–85
   PubMed Web of Science ®Google Scholar
• Kartner N., Evernden-Porelle D., Bradley G., Ling V. Detection of P-glycoprotein in multidrug resistant cell lines by monoclonal antibodies. Nature 1989; 316: 820–3
   Google Scholar
• Dubois M-F, Ferrieux C., Lebon P. Synergistic cytotoxic effects of recombinant human tumor necrosis factor interferons and heat-stress. Cancer Res 1989; 49: 5618–22
   PubMedGoogle Scholar
• Mattson K., Niiranen A., Holsti L., Pyrhönen S., Cantell K. Low dose of natural alpha interferon as maintenance therapy for small cell lung cancer. A phase III study. (Abstract) Proc Am Soc Clin Oncol 1989; 8: 227
   Google Scholar
• Carmichael J., Mitchell J. B., DeGraff W. G., et al. Chemosensitivity testing of human lung cancer cell lines using the MTT assay. Br J Cancer 1985; 57: 540–7
   Web of Science ®Google Scholar
• Nygren P., Fridborg H., Csoka K., et al. Detection of tumor-specific cytotoxic drug activity in vitro using the fluorometric microculture cytotoxicity assay and primary cultures of tumor cells from patients. Int J Cancer 1994; 56: 715–20
   PubMed Web of Science ®Google Scholar
• Carney D. N., Berendsen H., Bergh J., et al. Biological response modifiers in the management of small cell lung cancer: a consensus report. Lung Cancer 1989; 5: 143–5
   Google Scholar
• Ucer U., Bartsch H., Scheurich P., Pfizenmainer K. Biological effects of gamma-interferon on human tumor cells: Quantity and affinity of cell membrane receptors for gamma-IFN in relation to growth inhibition and induction of HLA-DR expression. Int J Cancer 1985; 36: 103–8
   PubMedGoogle Scholar
• Tovey M. G., Dron M., Mogensen K. E., et al. Isolation of Daudi cells with reduced sensitivity to interferon: II. On the mechanism of resistance. J Gen Virol 1983; 64: 2449–53
   Google Scholar
• Pfeffer L. M., Stebbing N., Donner D. B. Cytoskeletal association of human alpha-interferon-receptor complexes in interferonsensitive and resistant lymphoblastoid cells. Proc Natl Acad Sci USA 1987; 84: 3249–53
   PubMedGoogle Scholar
• Branca A. A., Baglioni C. Evidence that type I and II IFNs have different receptors. Nature 1981; 294: 768–70
   PubMed Web of Science ®Google Scholar
• Hovanessian A. G., Wood J. N. Anticellular and antiviral effects of pppA(2′p5′A)n. Virology 1980; 101: 81–90
   PubMedGoogle Scholar
• Krishnan I., Baglioni C. Elevated levels of (2′-5′)oligoadenylic acid polymerase activity in growth-arrested human lymphoblastoid Namalva cells. Mol Cell Biol 1981; 1: 932–8
   PubMedGoogle Scholar
• Fish E. N., Banerjee K., Stebbing N. The role of three domains in the biological activity of human interferon-α. J Interferon Res 1989; 9: 97–114
   PubMedGoogle Scholar